For adults with moderate to severe ulcerative colitis (UC) in whom TNF blockers did not work well, or after a different injection or pill (systemic therapy) when TNF blockers are not recommended by your healthcare provider

RINVOQ

Results

RINVOQ results that won't back down

RINVOQ was proven to help deliver results in two 8-week clinical trials in people with moderate to severe UC. Those who achieved clinical response at 8 weeks entered a maintenance trial, where RINVOQ helped deliver results at 1 year. See details below:

How soon did people feel symptom relief?

2 weeks — Most people experienced rapid symptom relief, including fewer bowel movements and bloody stools

8 weeks

  • Most people experienced symptom relief*
  • RINVOQ helped significantly reduce fatigue

*Based on the frequency of bowel movements, the amount of bloody stools, and the visible appearance of the colon lining.

Rapid symptom relief†    at 2 weeks

Graph showing the percentage of people who experienced rapid symptom relief at 2 weeks. Results are 27% for placebo (n=154) and 60% for RINVOQ 45mg (n=319) from Study 1. Results are 26% for placebo (n=174) and 63% for RINVOQ 45mg (n=341) from Study 2.

†Based on the frequency of bowel movements and the amount of bloody stools.

Symptom relief* at 8 weeks

Graph showing the percentage of people who experienced symptom relief at 8 weeks. Results are 27% for placebo (n=154) and 73% for RINVOQ 45mg (n=319) from Study 1. Results are 25% for placebo (n=174) and 74% for RINVOQ 45mg (n=341) from Study 2.

*Based on the frequency of bowel movements, the
 amount of bloody stools, and the visible appearance of the colon lining.

How soon could a doctor see visible colon lining repair?

8 weeks — RINVOQ helped deliver visible colon lining repair‡

1 year — Among patients who achieved clinical response at 8 weeks, RINVOQ helped deliver visible colon lining repair‡

‡Areas that were visually assessed may not represent repair of the
entire colon lining.

Visible colon lining repair‡ at 8 weeks

Graph showing the percentage of people who experienced visible colon lining repair at 8 weeks. Results are 7% for placebo (n=154) and 36% for RINVOQ 45mg (n=319) from Study 1. Results are 8% for placebo (n=174) and 44% for RINVOQ 45mg (n=341) from Study 2.

​

Visible colon lining repair‡ at 1 year

Results from 451 patients who achieved clinical response§

Graph showing the percentage of people who experienced visible colon lining repair at 1 year, among patients who achieved clinical response at 8 weeks. Results are 14% for placebo (n=149), 49% for RINVOQ 15mg (n=148), and 62% for RINVOQ 30mg (n=154) from Study 3.

§Defined by decrease in stool frequency, decrease in rectal bleeding, and endoscopic improvement from baseline, after 8 weeks of treatment with RINVOQ.

When did people experience remission, meaning few to no UC symptoms?

8 weeks and 1 year — RINVOQ helped people achieve remission in ulcerative colitis

Among people who achieved remission at 8 weeks, a majority experienced lasting steroid-free remission at 1 year

Remission at 8 weeks

Graph showing the percentage of people who experienced remission at 8 weeks. Results are 5% for placebo (n=154) and 26% for RINVOQ 45mg (n=319) from Study 1. Results are 4% for placebo (n=174) and 33% for RINVOQ 45mg (n=341) from Study 2.

​

Lasting steroid-free 
remission|| at 1 year

Among people who achieved 
remission at 8 weeks

Graph showing the percentage of people who experienced lasting steroid-free remission at 1 year among people who achieved remission at 8 weeks. Results are 22% for placebo (n=54), 57% for RINVOQ 15mg (n=47), and 68% for RINVOQ 30mg (n=58) from Study 3.

||Results from 159 patients who achieved remission after 8
 weeks of treatment with RINVOQ and were on steroids at
 baseline. Patients had few or no UC symptoms, achieved
 visible colon lining repair, and did not need steroids for at
 least 90 days immediately before the 1-year visit.

What long-term results are available for RINVOQ?

4 years — Some people taking RINVOQ for UC had visible colon lining repair‡

4 years — Some people taking RINVOQ for UC were in remission

In the less strict study at 4 years, everyone knew RINVOQ was used, which may have increased results. Results measured in RINVOQ-treated patients who met clinical response at 8 weeks (defined by decrease in stool frequency, decrease in rectal bleeding, and endoscopic improvement).

‡Areas that were visually assessed may not represent repair of the
entire colon lining.

Keep scrolling for safety considerations and real patient endoscopy images from RINVOQ clinical trials

Arrow down

SAFETY CONSIDERATIONS

RINVOQ may cause serious side effects, including:

  • Serious infections. RINVOQ can lower ability to fight infections. Serious infections, some fatal, occurred, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Cancer and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer.
  • Increased risk of major cardiovascular events such as heart attack, stroke, or death in people 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Blood clots, some fatal, in veins of the legs or lungs and arteries. This occurred more often in people 50+ with at least 1 heart disease risk factor.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.
  • Tears in the stomach or intestines; low blood sugar in people with diabetes; and changes in certain laboratory test results.

Learn more about these and the full Important Safety Information below. 

See what visible colon lining repair‡ in UC can look like

Real clinical trial patient endoscopy images

Adult patient with moderate to severe UC received RINVOQ 45 mg (induction) and 15 mg (maintenance), once daily. This patient did not achieve visible colon lining repair at Week 8, but did achieve visible colon lining improvement at 1 year.

In clinical trials, many patients showed visible colon lining improvement at 1 year with RINVOQ 15 mg compared to placebo. Results at 1 year were measured in RINVOQ-treated patients who achieved clinical response§ at Week 8.

Individual results may vary.

Your doctor will decide which maintenance dose (15 mg or 30 mg) is right for you. 

Endoscopic remission - Endoscopic remission in Crohn's is achieved when your doctor sees little to no damage in the colon lining, characterized by mild to inactive disease as seen on endoscopy. 

‡Areas that were visually assessed may not represent repair of the entire colon lining. 

§Defined by decrease in stool frequency, decrease in rectal bleeding, and endoscopic improvement from baseline, after 8 weeks of treatment with RINVOQ.